Enomoto M

No ORCID on file · 3 papers in corpus · active 2018-2022
2022
A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology.
Reproductive medicine and biology ·doi:10.1002/rmb2.12424

PurposeTo evaluate the efficacy of an oral gonadotropin-releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART).MethodsWe enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimu…

2019
Different anti-Műllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes.
Reproductive medicine and biology ·doi:10.1002/rmb2.12270

PurposeWe asked whether the relationship between anti-Műllerian hormone (AMH) value and the response to ovarian stimulation (OS) might be AMH value-related and differ for each regimen, aiming at getting clues as to how to choose OS protocol…

2018
Identifying a possible factor for the increased newborn size in singleton pregnancies after assisted reproductive technology using cryopreserved embryos, in comparison with fresh embryos.
Reproductive medicine and biology ·doi:10.1002/rmb2.12206

PurposeTo determine whether the cycle regimens that are used for endometrial preparation are associated with the birthweight (BW) after assisted reproductive technology (ART) using frozen-thawed embryo transfer (FET).MethodsThe BW of single…